Glioma Risks Associate With Genetic Polymorphisms of XRCC1 Gene in Chinese Population

ABSTRACT Glioma is the most common type of primary brain tumors in adults. Previous evidence indicates that the X‐ray repair cross‐complementing group 1 gene (XRCC1) is an important candidate gene which influencing the pathogenesis of glioma. This study aims to assess the potential associations betw...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of cellular biochemistry 2014-06, Vol.115 (6), p.1122-1127
Hauptverfasser: Feng, Xingjun, Miao, Guozhuan, Han, Yipeng, Xu, Yi, Wu, Huayun
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:ABSTRACT Glioma is the most common type of primary brain tumors in adults. Previous evidence indicates that the X‐ray repair cross‐complementing group 1 gene (XRCC1) is an important candidate gene which influencing the pathogenesis of glioma. This study aims to assess the potential associations between glioma risks and genetic polymorphisms of XRCC1 gene. A total of 1,286 Chinese Han ethnic subjects consisting of 638 glioma patients and 648 controls were recruited in this case‐control study. The genotyping of XRCC1 genetic polymorphisms (c.482C>T, c.1161G>A, and c.1804C>A) were conducted using the polymerase chain reaction‐restriction fragment length polymorphism (PCR‐RFLP), created restriction site‐PCR (CRS‐PCR) and DNA sequencing methods. Our data indicated that the allelic and genotypic frequencies of these genetic polymorphisms in glioma patients were significantly different from those of controls. We detected that the alleles/genotypes were statistically associated with the increased risks of glioma (for c.482C>T, TT versus (vs.) CC: OR = 2.24, 95% CI = 1.48–3.39, P A, AA vs. GG: OR = 1.62, 95% CI = 1.11–2.35, P = 0.012; A vs. G: OR = 1.19, 95% CI = 1.01–1.41, P = 0.040; for c.1804C>A, AA vs. CC: OR = 2.12, 95% CI = 1.45–3.11, P 
ISSN:0730-2312
1097-4644
DOI:10.1002/jcb.24753